Streetbeat News

Stock Prices

IRT

Independence Realty Trust (NYSE:IRT) is set to release its latest quarterly earnings report on October 30, 2023. Analysts estimate an earnings per share (EPS) of $0.29. The company's past performance shows a mix of positive and negative price changes post-earnings release. The stock is currently trading at $12.61, down 26.76% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:01 pm

BCC

Boise Cascade (NYSE:BCC) is set to release its quarterly earnings report on October 30, 2023. Analysts estimate an earnings per share (EPS) of $3.43. The company's stock performance has been generally positive, with shares trading at $90.81 as of October 26 and a 7.81% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:00 pm

BPMC

Barclays has maintained its Equal-Weight rating for Blueprint Medicines (NASDAQ:BPMC) and increased its price target from $46.00 to $58.00. Blueprint Medicines' shares are currently trading up 4.09% over the last 24 hours, at $57.48 per share. A move to $58.00 would account for a 0.9% increase from the current share price.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:00 pm

HUBG

JP Morgan has downgraded its rating of Hub Group (NASDAQ:HUBG) to Neutral with a price target of $84.00, a decrease from its previous target of $100.00. Hub Group's shares are currently trading down 10.23% at $65.55 per share. A move to $84.00 would account for a 28.15% increase from the current share price.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:00 pm

UVSP

Piper Sandler has maintained its Neutral rating for Univest Financial (NASDAQ:UVSP) but lowered its price target from $18.00 to $17.00. Univest Financial's shares are currently trading at $17.20, and a move to $17.00 would represent a 1.16% decrease from the current share price.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:00 pm

BMRN

PTCT

PTC Therapeutics Inc (PTCT) reported a delay in the planned submission of sepiapterin in phenylketonuria (PKU) in its Q3 earnings release. The FDA has pushed the timeline for FDA approval, requiring a 26-week nonclinical mouse study before seeking authorization. This delay will push the filing for FDA approval to the third quarter of next year. PTCT shares are down 22.40% at $18.60 on the last check Friday.

Portfolio Pulse from Vandana Singh

October 27, 2023 | 5:00 pm

R

Stephens & Co. has maintained its Equal-Weight rating for Ryder System (NYSE:R) but lowered its price target from $105.00 to $102.00. Ryder System's shares are currently trading at $93.22, and a move to $102.00 would represent a 9.42% increase.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:00 pm

MSFT

VFC

CNBC's Halftime Report discussed final trades, focusing on Microsoft (MSFT) and V.F. Corporation (VFC).

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:00 pm

APPF

AppFolio's shares are trading higher following the company's Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:58 pm

BIO

Bio-Rad Laboratories reported worse-than-expected Q3 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:58 pm